JCAR-020

N/A

Report date: 2023/01/04 15:14:36

Base Information

Drug NameJCAR-020
Drug Alias NameJCAR-020
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionT lymphocyte replacementsMucin-16 modulators
TargetsMucin-16
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer CenterJuno Therapeutics IncEureka Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer CenterJuno Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A